We serve Chemical Name:4-Bromo-3,5-difluoroaniline CAS:203302-95-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Bromo-3,5-difluoroaniline
CAS.NO:203302-95-8
Synonyms:4-bromo-3,5-difluoro-Benzenamine;4-bromo-3,5-difluoro-phenylamine;Benzenamine, 4-bromo-3,5-difluoro-;4-Bromo-3,5-difluoroaniline;ZR CF EF DE;MFCD00236593
Molecular Formula:C6H4BrF2N
Molecular Weight:208.003
HS Code:2921420090
Physical and Chemical Properties:
Melting point:99-101°C
Boiling point:223.7±35.0 °C at 760 mmHg
Density:1.8±0.1 g/cm3
Index of Refraction:1.570
PSA:26.02000
Exact Mass:206.949509
LogP:2.81
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN2811
Packing Group:III
Contact us for information like 4-bromo-3,5-difluoro-Benzenamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00236593 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenamine, 4-bromo-3,5-difluoro- Use and application,4-bromo-3,5-difluoro-phenylamine technical grade,usp/ep/jp grade.
Related News: A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 4-Bromo-3,5-difluoroaniline manufacturer The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 4-Bromo-3,5-difluoroaniline supplier A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 4-Bromo-3,5-difluoroaniline vendor A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 4-Bromo-3,5-difluoroaniline factory The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.
